Targeted Genetics to Present at the Rodman & Renshaw TechVest 7th Annual Healthcare Conference.
To access the live audio webcast for this conference, please log on to Targeted Genetics' website at http://www.targetedgenetics.com to register and download any necessary software. The audio presentation and slideshow will be available for replay following the event. Additional information about the Rodman & Renshaw conference can be found at www.rodmanandrenshaw.com.
About Targeted Genetics
Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis and other acquired and inherited diseases with significant unmet medical need. We use our considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Our product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure, Huntington's disease and hyperlipidemia. To learn more about Targeted Genetics, visit our website at: www.targetedgenetics.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements regarding our business strategy, our product development and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company's future plans are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, enrollment of patients, nature and results of our clinical trials, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q for the period ended June 30, 2005. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 2, 2005|
|Previous Article:||Restoration Force Focuses on 615,000 Customers Remaining out of Power Post-Wilma; FPL Shares Tips to Help Ensure Safe and Quick Restoration.|
|Next Article:||Acusphere Takes Occupancy of Commercial Manufacturing Facility in Tewksbury, Massachusetts.|